US20230278991A1
PlexusDx genetic insights, combined with comprehensive metabolic assessment, empower more informed shared decision-making around medication selection and realistic outcome expectations
7 Research Compounds All compounds HPLC-verified 98% purity COA on every batch Tirzepatide A dual-action research compound investigated in laboratory models involving GIP and GLP-1 receptor pathway analysis, incretin signaling dynamics, and metabolic cascade characterization
In clinical trials, about 74% of people on the 25-milligram oral dose experienced some gastrointestinal symptomsprimarily nausea, vomiting, or diarrhea
Transparency in these figures helps patients budget and compare options against branded alternatives or other treatment modalities
Symptoms of an allergic reaction may include rash, itching, swelling, severe dizziness, or difficulty breathing